| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Mitogen-activated protein kinase kinase kinase 8; Cancer Osaka thyroid oncogene; Proto-oncogene c-Cot; Serine/threonine-protein kinase cot; Tumor progression locus 2 |
| Entrez GeneID | 1326 |
| WB Predicted band size | Calculated MW: 53 kDa; Observed MW: 60 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human COT around the phosphorylation site of Thr290. AA range:256-305 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于Phospho-COT (Thr290)抗体的3篇参考文献示例(注：以下为模拟内容，实际文献需根据数据库检索确认)：
1. **文献名称**：*"Phosphorylation of COT at Thr290 regulates MAPK signaling and promotes tumorigenesis"*
**作者**：Johnson R, et al.
**摘要**：本研究揭示了COT激酶Thr290位点的磷酸化通过激活下游MAPK通路促进肿瘤细胞增殖，并利用特异性Phospho-COT (Thr290)抗体验证了其在多种癌症模型中的表达模式。
2. **文献名称**：*"A novel phospho-specific antibody reveals the role of COT Thr290 phosphorylation in inflammatory responses"*
**作者**：Chen L, et al.
**摘要**：开发了一种针对COT Thr290磷酸化位点的高特异性抗体，实验表明该位点的磷酸化通过调控NF-κB信号增强巨噬细胞的炎症反应。
3. **文献名称**：*"Targeting COT phosphorylation at Thr290 suppresses resistance to BRAF inhibitors in melanoma"*
**作者**：Martinez S, et al.
**摘要**：利用Phospho-COT (Thr290)抗体发现，抑制该位点磷酸化可降低黑色素瘤对BRAF抑制剂的耐药性，为联合治疗提供新靶点。
建议通过**PubMed**或**Google Scholar**以关键词“Phospho-COT Thr290”、“MAP3K8 phosphorylation”进一步检索真实文献。
The Phospho-COT (Thr290) antibody is designed to detect the phosphorylated form of COT (Cancer Osaka Thyroid, also known as MAP3K8 or TPL2), a serine/threonine kinase involved in inflammatory and oncogenic signaling. COT activates multiple pathways, including NF-κB and ERK/MAPK, by phosphorylating downstream targets like IκBα and MEK1/2. Its activity is tightly regulated through post-translational modifications, including phosphorylation at Thr290. This residue lies within the kinase domain, and its phosphorylation is critical for COT's catalytic activity, stability, and interaction with regulatory proteins such as p105 (NF-κB1). Dysregulation of COT signaling is linked to autoimmune diseases, inflammation, and cancers, particularly those driven by chronic inflammation.
The Phospho-COT (Thr290) antibody enables researchers to study COT activation status in response to stimuli such as cytokines (e.g., TNF-α, IL-1β) or stress signals. It is commonly used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to assess COT activation dynamics in cell lines, tissues, or disease models. Validation typically includes testing in COT-deficient cells or using phosphatase treatments to confirm phosphorylation specificity. This antibody aids in exploring COT's role in pathological contexts, including its crosstalk with other kinases and potential as a therapeutic target. Species reactivity generally covers human, mouse, and rat samples, depending on the product.
×
